Journey Medical Q2 net product revenue $14.9M, net loss narrows to $3.4M; DFD-29 PDUFA Nov 4

Journey Medical Corp

2024-Q2 EPS reported -$0.69 revenue$27,885,000

Total net product revenue $14.9M, down 12% YoY but up 14% sequentially from Q1 2024.
Net loss reduced to $3.4M ($0.17/sh) from $8.4M ($0.46/sh) in Q2 2023.
Adjusted EBITDA positive $0.3M vs negative $0.6M in prior-year quarter.
DFD-29 NDA for rosacea under FDA review with PDUFA goal date November 4, 2024.
Appointed Joseph M. Benesch as permanent CFO and Michael C. Pearce to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.